Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.64 |
| ▸ | JAK1 | P23458 | 8/20 | 0.58 |
| ▸ | JAK3 | P52333 | 6/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7977326 | 0.95 | JAK2 (0.59) | JAK2JAK1JAK3PTK2KDM4E | |
| SCHEMBL3208514 | 0.91 | JAK2 (0.64) | JAK2JAK1JAK3PTK2CSF1R | |
| SCHEMBL7977595 | 0.90 | JAK2 (0.76) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL2145108 | 0.89 | JAK2 (0.61) | JAK2JAK1JAK3PTK2 | |
| SCHEMBL7974148 | 0.89 | JAK2 (0.69) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL3216367 | 0.88 | JAK2 (0.82) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL7964535 | 0.82 | JAK2 (0.66) | JAK2JAK1JAK3PTK2TYK2 | |
| SCHEMBL13536665 | 0.82 | JAK2 (0.63) | JAK2JAK1JAK3PTK2KDM4E | |
| SCHEMBL13073248 | 0.81 | JAK2 (0.67) | JAK2JAK1JAK3PTK2IKBKB | |
| SCHEMBL13073243 | 0.81 | JAK2 (0.71) | JAK2JAK1JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2010010188-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.